» Articles » PMID: 35867269

Antitumor Activity of Chitosan-Coated Iron Oxide Nanocomposite Against Hepatocellular Carcinoma in Animal Models

Overview
Date 2022 Jul 22
PMID 35867269
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatocellular carcinoma (HCC) is among the most prevalent and lethal cancers worldwide. Chitosan-coated iron oxide nanocomposite (FeO/Cs) is a promising bio-nanomaterial for many biological applications. The objective of this research was to evaluate the anticancer efficacy of FeO/Cs against HCC in animal models. FeO nanoparticles were prepared and added to chitosan solution; then, the mixture was exposed to gamma radiation at a dose of 20 kGy. Rats have received diethylnitrosamine (DEN) orally at a dose of 20 mg/kg body weight 5 times per week during a period of 10 weeks to induce HCC and then have received FeO/Cs intraperitoneal injection at a dose of 50 mg/kg body weight 3 times per week during a period of 4 weeks. After the last dose of FeO/Cs administration, animals were sacrificed. DEN induced upregulation of PI3K/Akt/mTOR and MAPK (ERK, JNK, P38) signaling pathways and inflammatory markers (TLR4, iNOS, and TNF-α). DEN also decreases cleaved caspase-3 and increases liver enzymes (ALT, AST, and GGT) activities. Administration of FeO/Cs significantly ameliorated the above-mentioned parameters.

Citing Articles

A Comprehensive Review of Nanoparticle-Based Drug Delivery for Modulating PI3K/AKT/mTOR-Mediated Autophagy in Cancer.

Rahman M, Jalouli M, Bhajan S, Al-Zharani M, Harrath A Int J Mol Sci. 2025; 26(5).

PMID: 40076496 PMC: 11899884. DOI: 10.3390/ijms26051868.


Selective cytotoxic effects of nitrogen-doped graphene coated mixed iron oxide nanoparticles on HepG2 as a new potential therapeutic approach.

Demir Z, Sungur B, Bayram E, Ozkan A Discov Nano. 2024; 19(1):33.

PMID: 38386123 PMC: 10884380. DOI: 10.1186/s11671-024-03977-y.


Polymer composite microspheres loading Lu radionuclide for interventional radioembolization therapy and real-time SPECT imaging of hepatic cancer.

Xiao L, Li Y, Geng R, Chen L, Yang P, Li M Biomater Res. 2023; 27(1):110.

PMID: 37925456 PMC: 10625707. DOI: 10.1186/s40824-023-00455-x.


Hydrophilic Copolymers with Hydroxamic Acid Groups as a Protective Biocompatible Coating of Maghemite Nanoparticles: Synthesis, Physico-Chemical Characterization and MRI Biodistribution Study.

Charvatova H, Plichta Z, Hromadkova J, Herynek V, Babic M Pharmaceutics. 2023; 15(7).

PMID: 37514168 PMC: 10384990. DOI: 10.3390/pharmaceutics15071982.


The Role of TLR4 in the Immunotherapy of Hepatocellular Carcinoma: Can We Teach an Old Dog New Tricks?.

Papadakos S, Arvanitakis K, Stergiou I, Lekakis V, Davakis S, Christodoulou M Cancers (Basel). 2023; 15(10).

PMID: 37345131 PMC: 10216531. DOI: 10.3390/cancers15102795.


References
1.
Shetake N, Kumar A, Gaikwad S, Ray P, Desai S, Ningthoujam R . Magnetic nanoparticle-mediated hyperthermia therapy induces tumour growth inhibition by apoptosis and Hsp90/AKT modulation. Int J Hyperthermia. 2015; 31(8):909-19. DOI: 10.3109/02656736.2015.1075072. View

2.
Grosse S, Stenvik J, Nilsen A . Iron oxide nanoparticles modulate lipopolysaccharide-induced inflammatory responses in primary human monocytes. Int J Nanomedicine. 2016; 11:4625-4642. PMC: 5028097. DOI: 10.2147/IJN.S113425. View

3.
Sang M, Luo R, Bai Y, Dou J, Zhang Z, Liu F . Mitochondrial membrane anchored photosensitive nano-device for lipid hydroperoxides burst and inducing ferroptosis to surmount therapy-resistant cancer. Theranostics. 2019; 9(21):6209-6223. PMC: 6735518. DOI: 10.7150/thno.36283. View

4.
Guoyin Z, Hao P, Min L, Wei G, Zhe C, Changquan L . Antihepatocarcinoma Effect of L. in Mice by PI3K/Akt/mTOR and Nrf2/HO-1/NF-B Pathway. Evid Based Complement Alternat Med. 2017; 2017:8231358. PMC: 5474246. DOI: 10.1155/2017/8231358. View

5.
Wolf-Grosse S, Mollnes T, Ali S, Stenvik J, Nilsen A . Iron oxide nanoparticles enhance Toll-like receptor-induced cytokines in a particle size- and actin-dependent manner in human blood. Nanomedicine (Lond). 2018; 13(14):1773-1785. DOI: 10.2217/nnm-2017-0362. View